Protocol for the Examination of Resection Specimens From Patients With Primary Carcinoma of the Colon and Rectum
Diseases of the Colon & Rectum - Assessing the Quality of Rectal Cancer Pathology Reports in National Surgical Adjuvant Breast and Bowel Project Protocol NRG Oncology/NSABP R-04 - the latest #DCRJournal #ColorectalCancer
![Sensitization of FOLFOX-resistant colorectal cancer cells via the modulation of a novel pathway involving protein phosphatase 2A | bioRxiv Sensitization of FOLFOX-resistant colorectal cancer cells via the modulation of a novel pathway involving protein phosphatase 2A | bioRxiv](https://www.biorxiv.org/content/biorxiv/early/2021/07/23/2021.07.21.453259/F1.large.jpg)
Sensitization of FOLFOX-resistant colorectal cancer cells via the modulation of a novel pathway involving protein phosphatase 2A | bioRxiv
![Connection and distinction of tumor regression grading systems of gastrointestinal cancer - ScienceDirect Connection and distinction of tumor regression grading systems of gastrointestinal cancer - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0344033820306968-gr4.jpg)
Connection and distinction of tumor regression grading systems of gastrointestinal cancer - ScienceDirect
![Serosal surfaces, mucin pools, and deposits, Oh my: challenges in staging colorectal carcinoma | Modern Pathology Serosal surfaces, mucin pools, and deposits, Oh my: challenges in staging colorectal carcinoma | Modern Pathology](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fmodpathol.2014.128/MediaObjects/41379_2015_Article_BFmodpathol2014128_Fig1_HTML.jpg)
Serosal surfaces, mucin pools, and deposits, Oh my: challenges in staging colorectal carcinoma | Modern Pathology
![Protocol of the QUATTRO-II study: a multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as a first-line treatment in patients with metastatic colorectal cancer | BMC Cancer Protocol of the QUATTRO-II study: a multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as a first-line treatment in patients with metastatic colorectal cancer | BMC Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1186%2Fs12885-020-07186-5/MediaObjects/12885_2020_7186_Fig1_HTML.png)
Protocol of the QUATTRO-II study: a multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as a first-line treatment in patients with metastatic colorectal cancer | BMC Cancer
Protocol for the Examination of Resection Specimens From Patients With Primary Carcinoma of the Colon and Rectum
![Comprehensive review of targeted therapy for colorectal cancer | Signal Transduction and Targeted Therapy Comprehensive review of targeted therapy for colorectal cancer | Signal Transduction and Targeted Therapy](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41392-020-0116-z/MediaObjects/41392_2020_116_Fig1_HTML.png)